Published Studies on the Use of Thymidine Kinase Determination in Solid Tumors.

Svobodova S, Topolcan O, Holubec L, Treska V, Sutnar A, Rupert K, Kormunda S, Rousarova M, Finek J.
Prognostic importance of thymidine kinase in colorectal and breast cancer.
Anticancer Res. 2007 Jul-Aug;27(4A):1907-9.

He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S.
Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
Anticancer Res. 2006 Nov-Dec;26(6C):4753-9.

Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhang W, He Q.
Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Oncol Rep. 2006 Feb;15(2):455-61.

Li HX, Lei DS, Wang XQ, Skog S, He Q.
Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Oncol Rep. 2005 Jan;13(1):145-9.

Hallek M, Touitou Y, Levi F, Mechkouri M, Bogdan A, Bailleul F, Senekowitsch R, Emmerich B.
Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer.
Clin Chim Acta. 1997 Nov 28;267(2):155-66.

Letocha H, Eklöv S, Gronowitz JS, Norlen BJ, Nilsson S.
Deoxythymidine kinase in the staging of prostatic adenocarcinoma.
Prostate 1996; 29:15-9.

Ekman P, Lewenhaupt A.
Serum tumor markers in human prostatic carcinoma. The value of a marker panel for prognostic information.
Acta Oncol. 1991; 30:173-5.

Lewenhaupt A, Ekman P, Eneroth P, Nilsson B.
Tumor markers as prognostic aids in prostatic carcinoma.
Br.J.Urol. 1990; 66:182-7.

Larson A, Fritjofsson A, Norlen BJ, Gronowitz JS, Ronquist G.
Prostate specific acid phosphatase versus five other possible tumor markers: a comparative study in men with prostatic carcinoma.
Scand.J.Clin.Lab.Invest.Suppl. 1985; 179:81-8.

To read PDF files you need Acrobat Reader.